Faruqi & Faruqi Investigation: VBI Vaccines Inc.
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of VBI Vaccines Inc. (“VBI” or the “Company”) (NasdaqCM:VBIV) for potential breaches of fiduciary duties in connection with the sale of the Company to SciVac Therapeutics Inc. for approximately $77 million.
The Company’s stockholders will only receive 20.808356 common shares of SciVac for each share of VBI common stock they own, or approximately $2.69 per share. However, at least one analyst sets a VBI target price of $7.00 per share.
If you own common stock in VBI and wish to obtain information and protect your investments free of charge, please contact Juan Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.